Across TCGA pan-cancer cohorts, TMEM63A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM63A data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM63A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TMEM63A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where TMEM63A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.577	0.223	.006	17	view →
LSCC	DFS	Median	All	0.581	0.833	.002	14	view →
CCRCC	OS	Tertile	All	0.681	1.000	.013	4	view →
LUAD	DFS	Median	III,IV	0.315	0.948	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TMEM63A tumor-vs-normal RNA expression · all TMEM63A data types